STI and Coinfections Summary
Intended Learning Outcomes
Understand main features of syphilis and gonorrhoea.
Know basic features of bacteria involved.
Comprehend relation of pathogen features to disease.
Understand diagnosis, treatment, and prevention strategies.
Overview of STIs
Common bacterial STIs: Gonorrhoea, Syphilis, Chlamydia.
Over 300,000 infections annually (WHO).
Viruses and parasites also cause STIs (HIV lecture).
Gonorrhoea Trends
Increasing diagnoses in England: 35,000 in recent years.
Challenges in STI Control
Pregnancy complications and infertility.
Asymptomatic transmission.
Stigma and antimicrobial resistance.
Treponema pallidum (Syphilis)
Obligate pathogen, small genome (1039 genes).
Transmission: sexual and congenital (serious).
Disease stages: Primary, Secondary, Tertiary.
Symptoms of Syphilis
Primary: Painless chancre after 3 weeks.
Secondary: Fever, headache, lesions.
Tertiary: Localized symptoms after many years.
Virulence of Treponema pallidum
Chronic infections evade immune response.
No LPS, few stimulatory outer membrane proteins.
Antigenic variation and CNS invasion.
Diagnosis and Treatment of Syphilis
Blood tests for antibodies.
Treatment with penicillin; no known resistance.
Neisseria gonorrhoeae
Gram-negative beta-Proteobacteria, oval-shaped diplococcus.
Identified via microscopy; sensitive to dehydration.
Colonization and Symptoms of Gonorrhoea
Colonizes mucosa, adheres, and invades cells.
Symptoms: pain, discharge; many females asymptomatic.
Virulence Factors of Neisseria gonorrhoeae
Adhesion via Opa protein and pili.
Molecular mimicry for immune evasion.
Release of cytotoxins affecting fertility.
Diagnostics and Prevention
Nucleic acid amplification tests, microscopy, culture tests.
Preventative measures: screening and treatment of pregnant women.
Treatment and Resistance of Gonorrhoea
Treatment options include penicillin, azithromycin, fluoroquinolone.
Rising antimicrobial resistance; need for second-line treatments.
New Approaches and Future Outlook
Clinical trials for new antibiotics against "super-gonorrhoea."
Vaccine development ongoing to reduce incidence.